Annual report
4483.TEDINET S100RAOK
Period2022-04-01 → 2023-03-31
Filed2023-06-30
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 153
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥27.8bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥21.8bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥16.8bn | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥12.2bn | 2019-04-01 → 2020-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥10.1bn | 2018-04-01 → 2019-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥5.9bn | 2022-04-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥4.8bn | 2021-04-01 → 2022-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥5.9bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥4.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥3.6bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥2.2bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥1.4bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥4.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥3.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥2.5bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥1.5bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥1.0bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥4.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥3.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥98.6bn | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥62.1bn | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥58.3bn | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥26.9bn | at 2020-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥19.0bn | at 2019-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥34.0bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥30.9bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥64.5bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥31.2bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥28.3bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥64.5bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥31.2bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥28.3bn | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥13.1bn | at 2020-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥6.1bn | at 2019-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥22.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥13.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥19.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥7.7bn | at 2020-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥3.6bn | at 2019-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥4.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥3.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥3.2bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥3.1bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥1.8bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥22.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥8.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥9.1bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥3.9bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥330m | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | ¥28.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥18.1bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥4.9bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥1.2bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥71.17 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥57.74 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥46.54 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥31.46 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥23.86 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥67.69 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥54.16 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥43.48 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥29.99 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥21.71 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,025.89 | at 2023-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥551.17 | at 2022-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥504.59 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥252.22 | at 2020-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥132.38 | at 2019-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 65.5% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 50.2% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 48.8% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 48.7% | at 2020-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 32.3% | at 2019-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 8.9% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 10.9% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 12.0% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 15.9% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 25.7% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 1,346 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 966 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 757 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 503 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 441 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥9.4bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥8.0bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥6.3bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥4.8bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥3.6bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥2.0bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥1.6bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥1.8bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.7bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.0bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥830m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥753m | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.8bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥1.7bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥1.3bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥1.2bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥734m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥534m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥387m | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥73.2bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥41.4bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥42.5bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥18.4bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥9.3bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥13.4bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥12.1bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥59.8bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥29.3bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥27.8bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥11.4bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥5.3bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥33m | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥62m | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥22.08 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.54 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥13.8 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥10.99 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥9.15 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥21 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥20.2 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥12.89 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥10.48 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥12 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥10 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥950.74 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥517.6 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥497.17 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥218.75 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥114.64 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 81.7% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.7% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.6% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.0% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 3.0% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.2% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.7% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.4% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.9% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 62,910,608 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 56,514,208 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 55,935,808 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 25,975,042 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,552,521 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 348 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 305 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 265 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 224 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 174 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥277m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥277m |
| Dispensing Pharmacy Supportreportable segment | employees | at 2023-03-31 | 201 pure |
| Dispensing Pharmacy Supportreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥3.8bn |
| Dispensing Pharmacy Supportreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥3.6bn |
| Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥194m |
| Healthcare Big Datareportable segment | employees | at 2023-03-31 | 1022 pure |
| Healthcare Big Datareportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥19.2bn |
| Healthcare Big Datareportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥19.1bn |
| Healthcare Big Datareportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥83m |
| Tele Medicinereportable segment | employees | at 2023-03-31 | 120 pure |
| Tele Medicinereportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥5.0bn |
| Tele Medicinereportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥5.0bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥28.1bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥27.8bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥277m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥228m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥228m |
| Dispensing Pharmacy Supportreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥3.6bn |
| Dispensing Pharmacy Supportreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥3.4bn |
| Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥158m |
| Healthcare Big Datareportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥14.0bn |
| Healthcare Big Datareportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥13.9bn |
| Healthcare Big Datareportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥70m |
| Tele Medicinereportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥4.4bn |
| Tele Medicinereportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥4.4bn |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥22.0bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥21.8bn |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥228m |
| Healthcare Big Datareportable segment | employees | at 2023-03-31 | 348 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,656
| Item | Context | Value | Unit |
|---|---|---|---|
| Average number of temporary workers | Prior2YearInstant_NonConsolidatedMember | 35 | |
| Average number of temporary workers | Prior1YearInstant_NonConsolidatedMember | 31 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 29 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | － | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | － | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 2.245 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 2.912 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 1.966 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | － | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | － | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.421 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.450 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.534 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E35308-000HealthcareBigDataReportableSegmentMember | 1022 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E35308-000HealthcareBigDataReportableSegmentMember | 177 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E35308-000TeleMedicineReportableSegmentMember | 120 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E35308-000TeleMedicineReportableSegmentMember | 3 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E35308-000DispensingPharmacySupportReportableSegmentMember | 201 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E35308-000DispensingPharmacySupportReportableSegmentMember | 9 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 3 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | － | |
| Number of employees | CurrentYearInstant | 1346 | |
| Average number of temporary workers | CurrentYearInstant | 189 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 348 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 29 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 38.2 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 3.9 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 7274536 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E35308-000HealthcareBigDataReportableSegmentMember | 348 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E35308-000HealthcareBigDataReportableSegmentMember | 29 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 348 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 29 | |
| Research and development expenses research and development activities | CurrentYearDuration | 158000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E35308-000HealthcareBigDataReportableSegmentMember | 80000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E35308-000TeleMedicineReportableSegmentMember | 77000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E35308-000DispensingPharmacySupportReportableSegmentMember | 0 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 2855000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E35308-000HealthcareBigDataReportableSegmentMember | 1235000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E35308-000TeleMedicineReportableSegmentMember | 1504000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E35308-000DispensingPharmacySupportReportableSegmentMember | 115000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 62910608 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 62962208 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 62910608 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 62962208 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 18 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 38 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 87 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 227 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |